Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
Weight Loss · Triple Agonist
Retatrutide
Retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors, in late-phase clinical trials with the largest weight-loss results observed to date for an incretin therapy.
Retatrutide is an investigational triple agonist of the GLP-1, GIP, and glucagon receptors, in late-phase clinical trials with the largest weight-loss results observed to date for an incretin therapy. Mechanism: GLP-1 / GIP / Glucagon triple agonist. Typical route: Subcutaneous injection (weekly). FDA status: Not FDA-approved. In Phase 3 development by Eli Lilly. Compounded versions are not generally available because the molecule's manufacturing complexity and patent status limit pharmacy access.
Drug classGLP-1 / GIP / Glucagon triple agonist
Half-life~6 days
RouteSubcutaneous injection (weekly)
Phase 2 doses1, 4, 8, 12 mg/week
FDA statusInvestigational (Phase 3)
Compounded availabilityGenerally not available
Mechanism of action
Retatrutide simultaneously activates three receptors: GLP-1 (appetite suppression, insulin secretion), GIP (insulin sensitivity, lipid metabolism), and glucagon (increased energy expenditure, lipolysis). The triple mechanism is hypothesized to drive greater fat loss than dual GIP/GLP-1 agents like tirzepatide.
Dosing reference
Phase 2 trials used weekly subcutaneous injections at 1, 4, 8, and 12 mg dose levels. Maintenance dosing in development is not yet finalized; the manufacturer has not published a recommended regimen for clinical use.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. In Phase 3 development by Eli Lilly. Compounded versions are not generally available because the molecule's manufacturing complexity and patent status limit pharmacy access.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
U.S. telehealth providers that work with Retatrutide
Phase 3 trials are ongoing as of 2026. The earliest realistic FDA-approval timeline is 2027-2028. Watch the Eli Lilly investor announcements for trial readouts and submission timing.
How much weight loss did retatrutide produce in trials?
In the Phase 2 trial published in 2023, the 12 mg dose produced approximately 24% body weight loss at 48 weeks — the largest reduction seen for any GLP-1-class agent to date. Phase 3 results may confirm or moderate this finding.
Jastreboff AM, Kaplan LM, Frías JP, et al.Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.N Engl J Med. 2023;389(6):514-526.PMID: 37366315
Rosenstock J, Frias J, Jastreboff AM, et al.Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial.Lancet. 2023;402(10401):529-544.PMID: 37385275
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.
